EGFR and neoplasm: A previous study found that six of 12 NSCLC patients with a high AXL expression level in tumor tissue harbored EGFR activating mutation, and one of those six patients was treated with gefitinib and responded well.25 Together, these various observations indicate that the impact of high AXL expression on survival in EGRF‐TKI–naïve patients with EGFR‐mutated NSCLC needs further evaluation.